PPT Slide

ISV-205

• Diclofenac-based topical therapeutic, uses DuraSite system

• Addresses the TIGR protein

• Phase II data demonstrated efficacy

• Phase III to begin in 2001

• Partnered with Pharmacia Corp.

Previous slide

Next slide

Back to first slide

View graphic version